An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue 3, 2016, Pages 333-343

  Balkus, Jennifer E ^a,b,c   Brown, Elizabeth ^a,d   Palanee, Thesla ^e   Nair, Gonasagrie ^f   Gafoor, Zakir ^g   Zhang, Jingyang ^a   Richardson, Barbra A ^b,d   Chirenje, Zvavahera M ^h   Marrazzo, Jeanne M ^d   Baeten, Jared M ^b,c,d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Departments of Global Health   (United States)

^c Health Services and Epidemiology   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^h UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

African women; AIDS; clinical prediction rules; HIV 1 acquisition; risk score

Indexed keywords

AFRICAN; AGE; ALCOHOL CONSUMPTION; ARTICLE; FEMALE; FOLLOW UP; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MARRIED PERSON; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SCORING SYSTEM; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE; ADULT; AFRICA; EMPIRICAL RESEARCH; HIV INFECTIONS; ISOLATION AND PURIFICATION; MALE; PROCEDURES; RISK FACTOR; SEXUALITY; TRANSMISSION; VALIDATION STUDY; VIROLOGY;

ADULT; AFRICA; EMPIRICAL RESEARCH; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SEXUAL PARTNERS;

EID: 84959218183     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000974     Document Type: Article

References (44)

1. UNAIDS. UNAIDS Report on the Global AIDS Epidemic. 2013. Available at http://www.unaids.org/sites/default/files/media-asset/UNAIDS- Global-Report-2013-en-1.pdf. Accessed May 5, 2015.
2. Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir-emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Presented at: Conference on Opportunistic Infections and Retroviruses; 2013; Boston, MA.
3. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367: 411-422.
4. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376:1329-1337.
5. Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25:957-966.
6. Kahle E, Hughes J, Lingappa J, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62: 339-347.
7. Smith DK, Pals SL, Herbst JH, et al. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60:421-427.
8. Menza TW, Hughes JP, Celum CL, et al. Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis. 2009;36: 547-555.
9. Irungu EM, Heffron R, Mugo N, et al. Evaluation of a risk score tool to identify higher-risk HIV-1 serodiscordant couples for antiretroviral-based HIV-1 prevention. Presented at: HIV Research for Prevention Conference (Abstract #0A28.02); 2014; Cape Town, South Africa.
10. CDC. Pre-exposure Prophylaxis for the Prevention of HIV Infection in the United States - 2014; Clinical Providers' Supplement. Available at: http://www.cdc.gov/hiv/pdf/prepprovidersupplement2014.pdf. Accessed July 10, 2015.
11. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509-518.
12. Centers for Disease Control and Prevention. PrEP: A New Tool for HIV Prevention; 2012. Available at: http://www.cdc.gov/hiv/pdf/prevention- PrEP-factsheet.pdf. Accessed April 22, 2014.
13. UNAIDS. The Gap Report; 2014. Available at: http://www.unaids.org/ sites/default/files/media-asset/UNAIDS-Gap-report-en.pdf. Accessed August 17, 2015.
14. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov B, Csaki F, eds. Second International Symposium on Inference Theory. Budapest, Hungary: Akademiai Kiado; 1973:267-281.
15. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56: 337-344.
16. Pettifor AE, van der Straten A, Dunbar MS, et al. Early age of first sex: a risk factor for HIV infection among women in Zimbabwe. AIDS. 2004; 18:1435-1442.
17. Ramjee G, Wand H, Whitaker C, et al. HIV incidence among non-pregnant women living in selected rural, semi-rural and urban areas in KwaZulu-Natal, South Africa. AIDS Behav. 2012;16: 2062-2071.
18. Wand H, Ramjee G. The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: a cohort study. BMJ Open. 2012;2:e000285.
19. Mavedzenge SN, Weiss HA, Montgomery ET, et al. Determinants of differential HIV incidence among women in three southern African locations. J Acquir Immune Defic Syndr. 2011;58:89-99.
20. Glynn JR, Carael M, Auvert B, et al. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. AIDS. 2001;15(suppl 4):S51-S60.
21. Chersich MF, Rees HV. Causal links between binge drinking patterns, unsafe sex and HIV in South Africa: its time to intervene. Int J STD AIDS. 2010;21:2-7.
22. Chersich MF, Bosire W, King'ola N, et al. Effects of hazardous and harmful alcohol use on HIV incidence and sexual behaviour: a cohort study of Kenyan female sex workers. Global Health. 2014; 10:22.
23. WHO. Alcohol Use and Sexual Risk Behaviour: A Cross-Cultural Study in Eight Countries. 2005. Available at: http://www.who.int/substance- abuse/publications/alcohol-sexual-risk-crosscultural.pdf?ua=1. Accessed May 5, 2015.
24. Kalichman SC, Simbayi LC, Kaufman M, et al. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci. 2007;8:141-151.
25. White RG, Orroth KK, Glynn JR, et al. Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy? J Acquir Immune Defic Syndr. 2008;47:346-353.
26. Korenromp EL, White RG, Orroth KK, et al. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis. 2005;191(suppl 1): S168-S178.
27. Steen R, Wi TE, Kamali A, et al. Control of sexually transmitted infections and prevention of HIV transmission: mending a fractured paradigm. Bull World Health Organ. 2009;87:858-865.
28. Kagaayi J, Gray RH, Whalen C, et al. Indices to measure risk of HIV acquisition in Rakai, Uganda. PLoS One. 2014;9:e92015.
29. Buchbinder SP, Glidden DV, Liu AY, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014;14:468-475.
30. Verguet S, Stalcup M, Walsh JA. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa? Sex Transm Infect. 2013;89: 628-634.
31. Cremin I, Hallett TB. Estimating the range of potential epidemiological impact of pre-exposure prophylaxis: run-away success or run-away failure? AIDS. 2015;29:733-738.
32. Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART (O1-24). Presented at: Conference on Opportunitic Infections and Retroviruses; February 23-26, 2015; Seattle, WA.
33. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
34. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77ra29.
35. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.
36. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643-656.
37. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007; 369:657-666.
38. Dunkle KL, Jewkes RK, Brown HC, et al. Transactional sex among women in Soweto, South Africa: prevalence, risk factors and association with HIV infection. Soc Sci Med. 2004;59:1581-1592.
39. Jewkes R, Dunkle K, Ndunda M, et al. Transactional sex and HIV incidence in a cohort of young women in the stepping stones trial. J AIDS Clin Res. 2012;3:158.
40. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis. 2013:797-808.
41. Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312:390-409.
42. Herold BC, Dezzutti CS, Richardson BA, et al. Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr. 2014;66:65-73.
43. McCoy SI, Zheng W, Montgomery ET, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub- Saharan Africa. AIDS. 2013;27:1001-1009.
44. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. 2001;185:380-385.